Qi Pan, Ph.D., has over 14 years of experience in biotech and pharmaceutical R&D and gained in-depth knowledge on oncology and biotherapeutic drug discovery and development. Prior to Sema4, she was VP of R&D at Legend Biotech, a leading biotech company in the development of BCMA CAR-T therapy to treat multiple myeloma. At Legend Biotech, Qi led a team of scientists to work on innovative CAR-T preclinical research portfolio aiming to cure both hematological and solid tumors, and she was also responsible in setting Legend Biotech’s cancer immunotherapy R&D strategies. Previously, Qi worked in pharmaceutical companies such as Genentech and Boehringer Ingelheim and had led project teams to deliver multiple high quality biotherapeutic molecules from research to clinical development, including cancer indications and auto-immune indications. At Boehringer Ingelheim, Qi was also responsible for leading exploratory biotherapeutic portfolio for Tumor Immunology and Immune Modulation. Qi received her Ph.D. from Harvard University in the field of molecular and cellular biology.